Skip to main content
. 2020 Mar 26;9(4):802. doi: 10.3390/cells9040802

Figure 2.

Figure 2

CD38-mediated acquired resistance to PD-1/PD-L1 Inhibitors. Malignant cells resistant to checkpoint inhibition produce mediators such as ATR that lead to CD38 up-regulation via RARα. CD38 catalyzes the conversion of NAD+ into immunosuppressive adenosine via the CD38/CD203a/CD73 ectoenzymatic pathway. Adenosine interacts with A2AR and A2BR adenosine receptors on CD8+ T cells, thus suppressing cytotoxic activity.